Malaria Vaccine Market is expected to grow at a CAGR of 18.17% through 2031
The rising prevalence of malaria is expected to drive growth in the global malaria vaccine market over the forecast period, 2027-2031.
According to TechSci Research's report, “Malaria Vaccine Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031,” the global malaria vaccine market is projected to grow from USD 1.41 billion in 2025 to USD 3.84 billion by 2031, with an 18.17% CAGR. This can be ascribed to the increasing incidences of malaria, rising R&D activities,
and growing healthcare expenditure.
Global malaria
vaccine market is being driven by several factors, including increasing
investment in research and development of vaccines, the growing burden of
malaria in endemic regions, and the rising demand for effective malaria
prevention measures. The development of innovative vaccine technologies and
advances in understanding the complex nature of the malaria parasite are also driving market growth. In addition, government initiatives and partnerships
between public and private sectors to combat malaria are creating new
opportunities for vaccine manufacturers. Finally, increasing awareness of the importance of vaccination and the potential benefits of a malaria vaccine are also contributing to market growth. These factors are expected
to continue to drive the development of the global malaria vaccine market in the
coming years.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "Malaria Vaccine Market.”
Global Malaria
Vaccine Market can be segmented by vaccine type, by route
of administration, and by region.
Based on vaccine
type, Global Malaria Vaccine Market can be divided into Pre-Erythrocytic,
Erythrocytic, Multi-antigen, and Others. The pre-erythrocytic segment is
expected to dominate the global malaria vaccine market in the coming years due
to the effectiveness of pre-erythrocytic vaccines in preventing malaria
infections. Pre-erythrocytic vaccines target the early stages of the malaria
parasite's life cycle, when it infects the liver and begins replication. By targeting this stage of infection, pre-erythrocytic vaccines can prevent the parasite from causing disease symptoms and reduce disease spread. Additionally, pre-erythrocytic vaccines have shown promising results
in clinical trials and are in advanced stages of development. Several leading
vaccine candidates in the pre-erythrocytic segment are currently undergoing
clinical trials, indicating a significant focus on this area of the market.
Therefore, the pre-erythrocytic segment is expected to continue dominating the
global malaria vaccine market in the coming years.
The Global Malaria Vaccine Market is divided into North America, Europe, Asia-Pacific, South America, and the Middle East & Africa, by region. The Middle East and
Africa are expected to dominate the global malaria vaccine market in the coming years, owing to the region's high malaria prevalence. Sub-Saharan
Africa, in particular, bears a significant burden of the disease. As a result,
there is a high demand for effective malaria prevention measures, including
vaccines, in this region. Additionally, several key market players, including
GlaxoSmithKline and Sanofi, have a strong presence in the region and are
actively involved in malaria vaccine research and development. Furthermore,
government initiatives to combat malaria and expand access to healthcare in the region are expected to drive market growth.
Therefore, the Middle East and Africa region is likely to dominate the global
malaria vaccine market in the coming years.
Major companies operating in Global Malaria Vaccine Market are:
- GlaxoSmithKline, Plc.
- Novartis AG
- Takeda Pharmaceutical Company
- Sanaria Inc.
- Merck & Co.
- Johnson & Johnson
- Pfizer Inc.
- Serum Institute of India Private Limited
- Bharat Biotech International Limited
- Moderna Inc
Download Free Sample Report
Customers can also request a 10% free customisation on this report.
“Global malaria
vaccine market is rapidly evolving, with significant advancements in vaccine
technology and an increasing number of clinical trials for malaria vaccines.
The market is dominated by pre-erythrocytic vaccines, which target the early
stages of the malaria parasite's life cycle and have shown promising results in
clinical trials. There is also a growing focus on multistage vaccines that target multiple stages of the parasite's life cycle, potentially increasing efficacy. Technological advancements, such as the use of virus-like
particles and adjuvants, are also driving the development of more effective
vaccines. Additionally, there is a growing emphasis on the need for vaccines
that are effective against all parasite strains, including
drug-resistant strains. The increasing number of clinical trials and partnerships between public and private sectors bodes well for the future of the malaria vaccine market, with several promising vaccine candidates currently in advanced stages of development,” said Mr Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.
“Malaria Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), Region and Competition 2021-2031F”, has evaluated
the future growth potential of Global Malaria Vaccine Market and provides
statistics & information on market size, structure, and future market
growth. The report aims to provide state-of-the-art market intelligence and support decision-makers in making sound investment decisions. The report also identifies and analyses emerging trends, as well as essential drivers, challenges, and opportunities, in the Global Malaria Vaccine Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com